Search Results
Your search for Sandra M. Swain, MD matches 92 pages
Showing 51 - 92ASCO Completes Prototype for CancerLinQ™, Marking First Demonstration of a 'Learning Health System' to Transform Cancer Care
ASCO has completed a prototype of CancerLinQ™, the Society’s groundbreaking health information technology initiative to achieve higher quality, higher value cancer care with better outcomes for patients. The prototype was shown on March 27 at the National Press Club in Washington, DC, during an...
ASCO President's Priorities Aim to Build Bridges to Advance Cancer Care
Recognizing the need for greater interconnectivity to accelerate cancer care advances, Sandra M. Swain, MD, FACP, current ASCO President and Medical Director of Washington Cancer Institute MedStar Washington Hospital Center, selected “Building Bridges to Conquer Cancer” as her presidential theme....
ASCO President’s Personal Philanthropy Honors Founder Jane C. Wright, MD
During her term as ASCO President, Sandra M. Swain, MD, FACP, of the Washington Cancer Institute has kept a solid focus on her presidential and 2013 ASCO Annual Meeting theme of “Building Bridges to Conquer Cancer.” These bridges take many forms, spanning challenges to be overcome in oncology...
Women in Oncology: Trending in the Right Direction
According to ASCO President Sandra M. Swain, MD, FACP, an important part of her Presidential theme, “Building Bridges to Conquer Cancer,” is finding creative ways to ensure that we have enough oncologists to care for our burgeoning cancer patient population. Adding more women to the oncology...
Breakthroughs in Targeted Therapies for Breast Cancer Are Improving Patient Survival Rates
For more than 20 years, José Baselga, MD, PhD, has devoted his medical and scientific career to caring for breast cancer patients and the development of novel molecular targeted agents to treat the disease. From 1996 to 2010, he was Head of the Oncology Department of Vall d’Hebron University...
Congress Must Reverse Devastating Budget Cuts to Cancer Care
Sandra M. Swain, MD, FACP, ASCO President, issued the following statement on April 27, 2013: “Today, out of concern for public safety, Congress provided the Federal Aviation Administration enhanced flexibility in application of sequestration related cuts, including reversal of furlough requirements ...
ASCO Announces New Conflict of Interest Policy
In April, ASCO released its updated conflict of interest policy in the development and presentation of scientific research and educational content. The revised policy is designed to increase transparency in financial relationships between individuals and health-care companies and impose new...
How Is Sequestration Affecting Health Care?
The Budget Control Act of 2011, which calls for $1.2 trillion in federal funding cuts in national defense and nondefense programs, went into effect on March 1. The across-the-board cuts affect 21 agencies and programs directly involved in the health-care sector, including: Centers for Disease...
Sequestration's Impact on Cancer Care
On March 1, the deficit-budget mechanism known as sequestration took effect, triggering $85 billion in across-the-board cuts to most federal agencies over the remaining 7 months in fiscal year 2013. The total federal deficit reduction budget under the Budget Control Act of 2011 calls for $1.2...
ASCO Publishes New Conflict of Interest Policy
ASCO has released its new conflict of interest policy, ASCO Policy for Relationships With Companies, which updates its earlier policy in key ways that are designed to increase transparency in relationships with commercial interests. Comprehensive Framework The new policy establishes a more...
Cancer Organizations Recognize Sen. Shelby and Rep. DeLauro for Their Commitment to the Fight against Cancer
Sen. Richard Shelby (R-AL) and Rep. Rosa DeLauro (D-CT) were recognized recently by the American Society of Clinical Oncology, the American Association for Cancer Research, the Association of American Cancer Institutes, and Friends of Cancer Research for their outstanding commitment to cancer...
Expert Point of View: Sandra M. Swain, MD, FACP
Sandra M. Swain, MD, FACP, Immediate Past President of ASCO commented on the findings. “This is an exciting discovery and an example of early success in precision medicine. It’s targeting PI3K-delta, which is overactive in B-cell malignancies and is used in a disease that is very refractory to...
'Less Is More' with Regard to Adjuvant Radiation in Stage III Non–Small Cell Lung Cancer
Standard-dose conformal radiotherapy (60 Gy) is more effective and safer than high-dose radiotherapy (74 Gy) in patients with locally advanced stage III non–small cell lung cancer (NSCLC) undergoing chemotherapy, according to results of the phase III randomized, controlled Radiation Therapy...
Angelina Jolie's Disclosure of Prophylactic Bilateral Mastectomy: A Positive Example for Women with BRCA Mutations?
Angelina Jolie, in a New York Times article entitled “My Medical Choice,”1 disclosed that having a BRCA1 mutation and an estimated 87% risk of breast cancer, “I decided to be proactive and minimize the risk as much I could. I made a decision to have a preventive double mastectomy.” She was writing...
Business Summit Fosters Innovative Solutions to Oncology Market Challenges
To provide a forum for key cancer stakeholders to join with business, finance, and legal thought leaders to explore the future course for oncology, ASCO is co-hosting the seventh annual Cancer Center Business Summit on October 24 and 25 in Chicago, Illinois. Designed as a resource for the business...
ASCO Will Change with the Times
At the 2013 ASCO Annual Meeting, The ASCO Post caught up with new President Clifford A. Hudis, MD, Chief of the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center, New York, for a glimpse of his plans for ASCO in the coming year, and his thoughts on being elected ASCO...
ASCO Targets Health Disparities, Need for Research in Achieving Health Equity
The American Society of Clinical Oncology (ASCO), the Association of Black Cardiologists (ABC), and the Heart Failure Society of America (HSFA) recently held a Capitol Hill Briefing to draw attention to health disparities among minority and underserved patients and opportunities to achieve health...
ASCO Completes Electronic Data Sharing Standard for Breast Cancer Treatment
ASCO has completed the first phase in developing several sets of interoperability standards for cancer care data and overcoming the widespread inconsistencies that currently limit secure sharing of information between providers, patients, and researchers. The first standard, the Breast Cancer...
Robert S. Miller, MD, FACP, Appointed Editor-in-Chief of Cancer.Net
Robert S. Miller, MD, FACP, a medical oncologist and recognized authority in breast cancer, survivorship care, and consumer health informatics, has been appointed Editor-in-Chief of ASCO’s patient information website, Cancer.Net (www.cancer.net). He assumed this role at the 2013 ASCO Annual Meeting ...
International Cancer Corps Provides Valuable First-Time Volunteer Experience
Even as oncologists try to tackle the changing landscape of health care in the United States, many realize that both physicians and patients in this country are still in a better position than those fighting cancer abroad in low- and middle-income countries. In 2009, ASCO joined with Health...
Building Bridges to Conquer Cancer
One of the pleasures during my year as President was the ability to bring personal and professional passions and a sense of what really matters into focus for the work of our membership. My Presidential theme, Building Bridges to Conquer Cancer, reflected my particular interest in outreach to...
American Society of Clinical Oncology Honors Researchers, Patient Advocates, and Leaders of the Global Oncology Community
Leaders in cancer care will be recognized as part of the American Society of Clinical Oncology Special Awards Program at the 2014 ASCO Annual Meeting. The Special Awards recognize the dedication and significant contributions of researchers, patient advocates, and leaders of the global oncology...
Demanding More From Clinical Trials
“The function of the formal controlled clinical trial is to separate the relative handful of discoveries that prove to be true advances in therapy from a legion of false leads and unverifiable clinical impressions, and to delineate in a scientific way the extent of and the limitations that attend...
ASCO Through the Years: Past Presidents
This year ASCO celebrates it's 50th Anniversary. Here is a list of past ASCO Presidents over these 50 years: 2014-2015: Peter P. Yu, MD 2013-2014: Clifford A. Hudis, MD 2012-2013: Sandra M. Swain, MD, FACP 2011-2012: Michael P. Link, MD 2010-2011: George W. Sledge, Jr, MD 2009-2010: Douglas W....
'Physician Education Is Key' to Continued Advances in Geriatric Oncology
Several times during his lecture at the 2014 ASCO Annual Meeting, Stuart M. Lichtman, MD, FACP, FASCO, the recipient of the B.J. Kennedy Award for Scientific Excellence in Geriatric Oncology, emphasized, “Physician education is the key” to continued advances in geriatric oncology. He specified that ...
Aron Goldhirsch, MD, Receives 2014 Gianni Bonadonna Breast Cancer Award
Aron Goldhirsch, MD, was presented with the 2014 Gianni Bonadonna Breast Cancer Award and Lecture during the 2014 Breast Cancer Symposium, held recently in San Francisco. Dr. Goldhirsch is Director of the Multidisciplinary Program of Senology and Deputy Scientific Director at the European Institute ...
CLEOPATRA: Survival With Dual HER2 Blockade ‘Unprecedented’
In the final overall survival analysis of the phase III CLEOPATRA trial, HER2-positive metastatic breast cancer patients lived 15.7 months longer if they received pertuzumab (Perjeta) in addition to trastuzumab (Herceptin) and docetaxel, investigators reported at the European Society for Medical...
Impressive Survival Data for Women With HER2-Positive Breast Cancer Increase First-Line Use of Pertuzumab/Trastuzumab
"Impressive,” “outstanding,” and “unprecedented” are among the terms used to describe the 56.5-month overall survival for women with HER2-positive metastatic breast cancer receiving first-line treatment with pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and docetaxel in the...
Funding Promising Women Researchers: Women Who Conquer Cancer
Tomorrow’s cancer breakthroughs depend on making sure that talented young researchers have the chance to succeed today. Providing early funding for women in clinical oncology research is the singular goal of Women Who Conquer Cancer, a meaningful program of the ASCO-affiliated Conquer Cancer...
Researchers and Scientists Honored for Improving Cancer Prevention, Treatment, and Patient Care
The ASCO Special Awards recognize the dedication and significant contributions of researchers, patient advocates, and leaders of the global oncology community to enhancing cancer prevention, treatment, and patient care. Among this year’s awardees are an international leader in geriatric oncology...
CLEOPATRA Overall Survival Analysis: Significant Benefit for Pertuzumab Plus Trastuzumab/Docetaxel in HER2-Positive Metastatic Breast Cancer
As reported in The New England Journal of Medicine by Sandra M. Swain, MD, of Washington Cancer Institute, MedStar Washington Hospital Center, and colleagues, the final prespecified overall survival analysis in the phase III CLEOPATRA study showed a significant 15.7-month increase in median overall ...
The Importance of Supporting the Role of Women Leaders in Oncology
I am honored to be the 52nd President of ASCO and thrilled to have followed in the steps of six remarkable women to hold this important leadership position in a professional Society that represents nearly 40,000 oncologists around the world caring for people with cancer. My six female predecessors...
CLEOPATRA Study: Significant Overall Survival Benefit of Adding Pertuzumab to Trastuzumab/Docetaxel in HER2-Positive Metastatic Breast Cancer
As reported in The New England Journal of Medicine by Swain et al, the final prespecified overall survival analysis in the phase III CLEOPATRA study showed a significant 15.7-month increase in median overall survival over 50 months of follow-up with the addition of pertuzumab (Perjeta) to...
NSABP B-38 Trial Shows No Benefit of Adding Fourth Drug to Standard Adjuvant Treatment in Women With Node-Positive Breast Cancer
Anthracycline- and taxane-based three-drug chemotherapy regimens have proven benefit as adjuvant therapy for early-stage breast cancer. As reported in Journal of Clinical Oncology by Sandra M. Swain, MD, FACP, of Washington Cancer Institute–MedStar Washington Hospital Center, and colleagues,...
ASCO 2013: New Drug Targeting PI3K-delta Shows Strong Activity in Early Trial for High-risk Chronic Lymphocytic Leukemia
Results from a phase I study of a new oral targeted drug, idelalisib (GS-1101), show the agent has potential as a therapy for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL). The drug produced rapid and long-lasting tumor shrinkage in half of the patients treated with...
ASCO 2013: Standard-dose Radiation Is Superior to High-dose Radiation for Patients with Locally Advanced Stage III NSCLC Undergoing Chemotherapy
A phase III trial in patients with stage III non–small cell lung cancer (NSCLC) concluded that standard-dose radiotherapy (60 Gy) is safer and more effective than high-dose radiotherapy (74 Gy), extending survival by 9 months and causing fewer treatment-related deaths. While 60 Gy is already...
ASCO 2013: Men’s Fitness in Middle Age Protects against Developing and Dying from Cancer Later in Life
Findings from a large, prospective 20-year study indicate that a high level of cardiovascular fitness in middle age reduces men’s risk of developing and dying from lung and colorectal cancer, two of the most common cancers affecting men. Better fitness also reduces the risk of dying from,...
ASCO 2013: Phase I Trial Suggests Ipilimumab and PD-1 Drug Nivolumab May Be Better Together than Alone for Advanced Melanoma
Results from a phase I study show that combination therapy with ipilimumab (Yervoy) and the investigational antibody drug nivolumab led to lasting tumor shrinkage in approximately half of patients with aggressive, advanced melanoma. The results will be presented at the 2013 ASCO Annual Meeting in...
Congress Must Reverse Devastating Budget Cuts to Cancer Care
“Today, out of concern for public safety, Congress provided the Federal Aviation Administration enhanced flexibility in application of sequestration related cuts, including reversal of furlough requirements imposed on air traffic controllers. Individuals with cancer deserve no less....
Statement by ASCO President Sandra M. Swain, MD, FACP, in Support of the Rally for Medical Research, April 8, 2013
A strong, stable federal investment in cancer research, prevention, and treatment is critical to continue the progress we are making for the more than 1.66 million Americans newly diagnosed with cancer every year. ASCO calls on Congress to renew its commitment to this life-sustaining research. As...
ASCO Completes Prototype for CancerLinQ™, Marking First Demonstration of a “Learning Health System” to Transform Cancer Care
The American Society of Clinical Oncology announced yesterday that it has completed a prototype of CancerLinQ™, the Society’s groundbreaking health information technology (HIT) initiative to achieve higher quality, higher value cancer care with better outcomes for patients. The...
ASCO President: Sequestration Will Have Shattering Impact on Entire U.S. Cancer Enterprise
Statement by ASCO President Sandra M. Swain, MD, FACP, American Society of Clinical Oncology: Today marks the beginning of sequestration, the unprecedented automatic budget cuts that immediately take effect across the federal government—after months of futile negotiations by the President...
